Targeted disruption of the murine erythroid band 3 gene results in spherocytosis and severe haemolytic anaemia despite a normal membrane skeleton

Christopher D. Southgate, Ph.D., Esq. is a senior patent attorney with more than two decades of experience helping biotechnology companies, research institutions, and innovators protect groundbreaking life sciences technologies. His practice focuses on patent strategy, patent procurement, portfolio management, freedom-to-operate analyses, due diligence, and intellectual property counseling for biotechnology and pharmaceutical clients.